{"entity":{"id":"nct07428044","kind":"trial","name":"A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of trastuzumab deruxtecan in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","summary":"A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07428044 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 14 participants, started 2026-02-13 and due to reach its primary completion in 2027-02-13. Interventions recorded: Trastuzumab Deruxtecan. Conditions listed: Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer Stage II; Non-Small Cell Lung Cancer Stage IIIA; Non-Small Cell Lung Cancer Stage IIIB. Primary outcome: Major Pathologic Response/MPR Rate. Lung eligibility wording from the registry: \"* Pathologically documented NSCLC\". Sites: Canada, United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07428044","url":"https://clinicaltrials.gov/study/NCT07428044"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["her2-mutant-nsclc","resectable-nsclc"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["trastuzumab-deruxtecan"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07428044","phase":"2","setting":"A Phase II Trial of Neoadjuvant Trastuzumab Deruxtecan for Patients With Stage II-III HER2-Amplified or HER2-Mutated Non-Small Cell Lung Cancer (HERCULES)","sponsor":"Memorial Sloan Kettering Cancer Center","enrolled":14,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07428044/","neighbours":{"cancer":[{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}